Blue Bell, PA – According to filings with the U.S. Securities and Exchange Commission, Seneca Therapeutics is raising $5,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, James Hussey played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Seneca Therapeutics

Our mission is to develop a pipeline of best-in-class oncolytic immunotherapeutics that are highly effective in treating cancer patients with solid cancers. At Seneca Therapeutics, we believe a cure for cancer is within our lifetime and we are working with urgency to see this promising possibility become a reality. Seneca Therapeutics, Inc. (Seneca) is developing a pipeline of novel cancer agents using the nonpathogenic Seneca Valley Virus isolate 001 (SVV-001). The first product anticipated to be in later stage clinical trials in 2021 is SVV-001 itself. SVV-001 is a targeted immunotherapy that selectively kills cancer cells expressing the SVV-001 receptor, TEM-8, and converts the tumor microenvironment from cold to hot. SVV-001 is expected to synergize with immune checkpoint inhibitors and other cancer agents to significantly benefit more cancer patients.

To learn more about Seneca Therapeutics, visit http://senecatherapeutics.com/

Contact:
James Hussey, Chief Executive Officer
484-883-9725
jhussey@senecatherapeutics.com
https://www.linkedin.com/in/james-hussey-5b511148/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved